MitoTempol

PreclinicalSmall molecule

UUniversity of Delaware

MitoTempol is one of 11 small molecule programs targeting Vascular Function. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vascular FunctionCompleted

Vascular FunctionPreclinical

Completed

Competition

Competitive Landscape

12 competitors in Vascular Function

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Ultram

WWim Janssens

Approved

1 3

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

2 4

Miochol

BBausch Health Americas, Inc.

Phase 1

1 5

L-Citrulline

AAsklepion Pharmaceuticals, LLC

Phase 1

1 6

S-Equol

AAusio Pharmaceuticals, LLC

Phase 2

1 7

Endothelin-1

MMedical University of Vienna

Phase 1

2 8

BQ-123

MMedical University of Vienna

Phase 1

1 9

BH4

VVA Office of Research and Development

Phase 1

1 10

MitoTempol

UUniversity of Delaware

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vascular Function1 trial

Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline

Completed·UUniversity of Delaware·N/A·NCT06466655·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MitoTempol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MitoTempol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MitoTempol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Delaware company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Delaware

MitoTempol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vascular Function1 trial

References

Drug Info

Quick Facts

Related News